Clinical Trial Update: R.E.C.K vs Exparel in Robotic Nephrectomy [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing R.E.C.K to Exparel for pain management in robotic nephrectomy, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Exparel (liposomal bupivacaine)
• R.E.C.K

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Renal Carcinoma, Nephrectomy / Methods | Phase 3 | Status: RECRUITING